Abstract
B cells are once again gaining prominence as important programmers of CD4 T cell responses. With widespread use of B cell depletion therapy in the clinic, proving effective in treating diseases previously considered T cellmediated, the time is right for a re-appraisal of the B cell. Though typically considered weak, Th2 driving APC, it is now clear that they are necessary for a robust and long-lived CD4 T cell response in many settings. The sphere of B cell influence extends well beyond that of simply antibody production; antigen presentation, cytokine secretion, costimulation and development of lymphoid tissue architecture are all critical aspects of B cell immunobiology, the absence of which has serious impacts for T cell priming and memory. The aim of this review is to look at non-antibody mediated B cell function and to ask how, where and when do B cells influence the CD4 T cell response?
Keywords: B cell, T cell, antigen presentation, TLR, memory, cell responses, antibody production, B cell immunobiology, CD4 T cell response, dendritic cells, protein antigens, gross abnormalities, memory cells, lymphoid organogenesis, amateur
Infectious Disorders - Drug Targets
Title:B Cells: Programmers of CD4 T Cell Responses
Volume: 12 Issue: 3
Author(s): Tom A. Barr, Mohini Gray and David Gray
Affiliation:
Keywords: B cell, T cell, antigen presentation, TLR, memory, cell responses, antibody production, B cell immunobiology, CD4 T cell response, dendritic cells, protein antigens, gross abnormalities, memory cells, lymphoid organogenesis, amateur
Abstract: B cells are once again gaining prominence as important programmers of CD4 T cell responses. With widespread use of B cell depletion therapy in the clinic, proving effective in treating diseases previously considered T cellmediated, the time is right for a re-appraisal of the B cell. Though typically considered weak, Th2 driving APC, it is now clear that they are necessary for a robust and long-lived CD4 T cell response in many settings. The sphere of B cell influence extends well beyond that of simply antibody production; antigen presentation, cytokine secretion, costimulation and development of lymphoid tissue architecture are all critical aspects of B cell immunobiology, the absence of which has serious impacts for T cell priming and memory. The aim of this review is to look at non-antibody mediated B cell function and to ask how, where and when do B cells influence the CD4 T cell response?
Export Options
About this article
Cite this article as:
A. Barr Tom, Gray Mohini and Gray David, B Cells: Programmers of CD4 T Cell Responses, Infectious Disorders - Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/187152612800564446
DOI https://dx.doi.org/10.2174/187152612800564446 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
Call for Papers in Thematic Issues
New Frontiers in Infectious Disease Research: Small-Molecule Probes and Biomarker Identification
The biological relevance of small-molecule chemical probes targeting a disease model is crucial in the early stages of drug discovery. The integration of omics technologies such as genomics, proteomics, metabolomics, immunomic, and cellular levels has greatly enhanced the ability to identify novel biomarkers and understand the complex interactions between pathogens ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Elabela Peptide: An Emerging Target in Therapeutics
Current Drug Targets Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Current Pharmaceutical Biotechnology Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design Disruption of Cell Death Signaling in Cancer: Impact on Disease Prognosis and Response to Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Artemia species: An Important Tool to Screen General Toxicity Samples
Current Pharmaceutical Design FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract
Current Drug Targets Electrocatalytic Determination of 6-Mercaptopurine Using Multiwall Carbon Nanotubes Paste Electrode in the Presence of Methyldopa
Current Nanoscience Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Synergism of Curcumin and Cytarabine in the Down Regulation of Multi-Drug Resistance Genes in Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy IMPDH2 Positively Impacts the Proliferation Potential of Hepatoblastoma Cells by Activating JunB Signaling Pathway
Current Molecular Pharmacology Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Mitigative Effects of a Combination of Multiple Pharmaceutical Drugs on the Survival of Mice Exposed to Lethal Ionizing Radiation
Current Pharmaceutical Biotechnology Tyrosine Kinase Inhibitor Resistance and Epigenetic Regulation of SHP1 Phosphatase Expression in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Immunomodulation Via Targeted Inhibition of Antigen Receptor Signal Transduction
Cardiovascular & Hematological Disorders-Drug Targets Applied Proteomics in Companion Animal Medicine
Current Proteomics Novel Immunotherapeutic Strategies for Invasive Fungal Disease
Current Drug Targets - Cardiovascular & Hematological Disorders